The goal of the ‘Outcome Measures in Rheumatology’ (OMERACT) process is to select domains and/or outcome measures for clinical trials in each defined disease category according to truth, discrimination and feasibility. OMERACT IV, held in Cancun, Mexico, April 1998, included the module ‘Systemic Lupus Erythematosus (SLE)’, designed to define a preliminary core set of outcome domains for randomized controlled trials and longitudinal observational studies (LOS). Although specific measures to be used in clinical trials of SLE have yet to be determined, both randomized controlled trials and longitudinal observation studies groups recommended that outcome be assessed in terms of disease activity and damage in all organ systems involved, as well as by health related quality of life, meaningful to patients, and adverse events. These recommendations were ratified by the majority of participants. In a heterogeneous patient population such as SLE, it is recognized that any individual measure of clinical response may reflect only a portion of what might be termed the ‘true outcome’. A responder index could integrate such relatively independent measures of outcome into a single assessment, potentially increasing statistical power and decreasing sample size. Results from randomized controlled trials currently underway assessing these outcome domains are eagerly awaited, and are expected to rapidly advance the field
Boers M , Tugwell P for the OMERACT Committee. Conference on outcome measures in rheumatoid arthritis clinical trials . J Rheumatol1993; 20: 526–591 .
2.
Tugwell P , Brooks P , Boers M . OMERACT II: Conference on outcome measures in rheumatoid arthritis clinical trials . J Rheumatol1995; 22: 979–999; 1185–1207; 1339–1433 .
3.
Boers M , Brooks P , Strand V , Tugwell P . The OMERACT filter for outcome measures in rheumatology . J Rheumatol1998; 25: 198–199 .
4.
Tugwell P , Bombardier C . A methodologic framework for developing and selecting endpoints in clinical trials . J Rheumatol1982; 9: 758–762 .
5.
Austin HA , Klippel JH , Balow JE et al. Therapy of lupus nephritis . New Engl J Med1986; 314: 614–619 .
6.
Steinberg AD , Steinberg SC . Long term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide vs . those treated with prednisone only. Arthritis Rheum1991; 34: 945–950 .
7.
Boumpas DT , Austin HA , Vaughn EM et al. Controlled trial of pulse methylprednisolone vs. two regimens of pulse cyclophosphamide in severe lupus nephritis . Lancet1992; 340: 741–745 .
8.
Bansal VK , Beto JA . Treatment of lupus nephritis: a meta-analysis of clinical trials . Am J Kidney Dis1997; 29: 193–199 .
9.
Gourley MF , Austin HA , Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis . Ann Intern Med1996; 125: 549–557 .
10.
The Canadian Hydroxychloroquine Study Group . A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus . N Engl J Med1991; 324: 150–154 .
11.
Smolen JS . Clinical and serological features. In: Smolen JS , Zelinski CC (eds). Systemic Lupus Erythematosus: Clinical and Experimental Aspects. Springer Verlag: Berlin , 1987, pp 170–196.
12.
Liang MH , Socher SA , Roberts WN , Esdaile JM . Measurement of systemic lupus erythematosus activity in clinical research . Arthritis Rheum1988; 31: 817–825 .
13.
Liang MH , Socher SA , Larson MG , Schur PH . Reliability and validity of six systems for the clinical assessment of disease activity in SLE . Arthritis Rheum1989; 32: 1107–1118 .
14.
Bombardier C , Gladman DD , Urowitz MB et al. The development and validation of the SLE Disease Activity Index (SLEDAI) . Arthritis Rheum1992; 35: 630–640 .
15.
Gladman DD , Goldsmith CH , Urowitz MB et al. Crosscultural validation and reliability of 3 disease activity indices in SLE . J Rheumatol1992; 19: 608–611 .
16.
Symmons DPM , Coppock JS , Bacon PA et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus . Q J Med1988; 69: 927–937 .
17.
Stoll T , Stucki G , Malik J et al. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus . Ann Rheum Dis1996; 55: 756–760 .
18.
Hay EM , Bacon PA , Gordon C et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus . Q J Med1993; 86: 447–458 .
19.
Vitali C , Bencivelli W , Isenberg DA et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research: I. A descriptive analysis of 704 European lupus patients . Clin Exp Rheumatol1992; 10: 527–539 .
20.
Vitali C , Bencivelli W , Isenberg DA et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research: II. Identification of the variables indicative of disease activity and their use in the development of an activity score . Clin Exp Rheumatol1992; 10: 541–547 .
21.
Bencivelli W , Vitali C , Isenberg DA et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research: III. Development of a computerized clinical chart and its application to the comparison of different indices of disease activity . Clin Exp Rheumatol1992; 10: 549–554 .
22.
Bombardieri S , Vitali C , Capioni L et al. Activity criteria in systemic lupus erythematosus . Clin Exp Rheum1999; 12 (Suppl 11(HD)): S45–S48 .
23.
Aringer M , Smolen JS , Graninger WB . Severe infections in plasmapheresis treated systemic lupus erythematosus . Arthritis Rheum1998; 41: 414–420 .
24.
Petri M , Lahita R , McGuire J et al. Results of the GL701 (DHEA) multicenter steroid sparing SLE study . Arthritis Rheum1997; 40: S327–S327 .
Petri M , Buyon J , Skovron ML et al. Disease activity and health status (SF-36) in post menopausal systemic lupus erythematosus: the SELENA trial . Arthritis Rheum1997; 40: S208–S208 .
27.
Vitali C , Bencivelli W , Mosca M et al. Development of a clinical chart to compute different disease activity indices for systemic lupus erythematosus . J Rheumatol1999; 26 (2): 498–501 .
28.
Gladman DD , Ginzler E , Goldsmith C et al. Workshop report: SLICC: development of a damage index for SLE . J Rheumatol1992; 19: 1820–1821 .
29.
Gladman DD , Ginzler E , Goldsmith C et al. The SLICC/ACR damage index for SLE . Arthritis Rheum1992; 35: S209–S209 .
30.
Gladman DD , Ginzler E , Goldsmith C et al. The development and initial validation of the SLICC/ACR damage index for SLE . Arthritis Rheum1996; 39: 363–369 .
31.
Stoll T , Seifert B , Isenberg DA . SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus , Br J Rheumatol1996; 35: 248–254 .
32.
Hochberg MC , Sutton JD . Physical disability and psychosocial dysfunction in SLE . J Rheumatol1988; 15: 959–964 .
33.
Hochberg MC , Engle EW , Pruitt A et al. Correlation of disease activity with physical disability in SLE . Arthritis Rheum1990; 33S: R222–R222 .
34.
Burckhardt CS , Archenholtz B , Bjelle A . Quality of life of women with SLE: a comparison with women with RA . J Rheumatol1993; 20: 977–981 .
35.
Burckhardt CS , Archenholtz B , Bjelle A . Measuring the quality of life of women with RA or SLE: a Swedish version of the QOLS . Scand J Rheumatol1992; 21: 190–195 .
36.
Radloff LS . CES-D Scale: a self report depression scale for research in the general population . Appl Psychol Med1977; 4: 385–401 .
37.
Petri M . Invited response . In: Strand V ed. Proceedings: Biologic Agents in Autoimmune Disease IV. Arthritis Foundation: Atlanta, GA , 1996, pp 269–274.
38.
Gladman DD , Urowitz MB , Fortin P et al. Workshop Report: SLICC Conference on Assessment of Lupus Flare and QOL Measures in SLE . J Rheumatol1995; 23: 1953–1955 .
39.
Gladman DD , Urowitz MB , Ong A , Gough J . A comparison of 5 health status instruments in patients with SLE . Lupus1996; 5: 190–195 .
40.
Stewart AL , Hays RD , Ware JE . The MOS short-form general health survey . Med Care1988; 26: 724–734 .
41.
Ware JE , Sherbourne CD . The MOS SF-36 item short-form health survey (SF-36): conceptual framework and item selection . Med Care1992; 30: 473–483 .
42.
Dobkin PL , Fortin PR , Joseph L et al. Psychosocial contributors to mental and physical health in patients with SLE . Arthritis Care Res1998; 11: 23–31 .
43.
Petri M , Buyon J , Skovron ML et al. Disease activity and health status (SF-36) in post menopausal SLE: the SELENA trial . Arthritis Rheum1997; 40: S208–S208 .
44.
Gilboe I-M , Kvien TK , Husby G . Health impact in SLE compared to RA and healthy controls . Arthritis Rheum1997; 40: S209–S209 .
45.
Gordon C , Exley AR , Clay C et al. Changes in SF-36 scores in SLE with change in disease activity measured by the BILAG index . Arthritis Rheum1997; 40: S112–S112 .
46.
Gladman DD , Urowitz M , Gough J , MacKinnon A . Fibromyalgia is a major contributor to quality of life in lupus . J Rheumatol1997; 24: 2145–2148 .
47.
Mak VC , Bruce IN , Gladman DD , Urowitz MB . Factors associated with fatigue in SLE patients . Arthritis Rheum1997; 40: S208–S208 .
48.
Stoll T , Stucki G , Malik J , Pyke S , Isenberg D . Association of the Systemic Lupus International Collaborating Clinics American College of Rheumatology damage index with measures of disease activity, health status in patients with systemic lupus erythematosus . J Rheumatol1997; 24: 309–313 .
49.
Gladman DD , Urowitz MB , Ong A , Gough J , MacKinnon A . Lack of correlation among 3 outcome measures in SLE: disease activity, damage and quality of life . Clin Exp Rheumatol1996; 14: 305–308 .
50.
Stoll T , Gordon C , Seifert B et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus . J Rheumatol1997; 24: 1608–1614 .
51.
Fortin PR , Abrahamowicz M , Nevikke C et al. Impact of disease activity and cumulative damage on the health of lupus patients . Lupus1998; 7: 101–107 .
52.
Wekking EM . Psychiatric symptoms in SLE: an update . Psychosom Med1993; 55: 219–228 .
53.
Aranow C , Soliman N , Ginzler E . Lupus flares: impressions by patients and physicians . Arthritis Rheum1997; 40: S208–S208 .
54.
Strand V , Gladman D , Isenberg D , Petri M , Smolen J , Tugwell P . Outcome measures to be used in clinical trials in systemic lupus erythematosus . J Rheumatol1999; 26: 490–497 .
55.
Smolen J , Strand V , Cardiel M et al. Randomized clinical trials and longitudinal observational studies in SLE: consensus on a preliminary core set of outcome domains . J Rheumatol1999; 26: 504–507 .
